Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors

NCT05957081 is registered in ClinicalTrials.gov with PharmAbcine as lead sponsor.

NCT NCT05957081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05957081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b, First-in-Human, Open Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of PMC-309 (Anti-VISTA), as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
PharmAbcine
Phase
Phase 1
Overall status
Recruiting
Start date
January 3, 2024
Completion date
April 30, 2030
Enrollment
67 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid tumors